Skip to content

We understand and support the need for increased disclosure of clinical trial data, and we continue to work with the Association of the British Pharmaceutical Industry (ABPI) on this important topic to ensure that any emerging regulations will result in benefits for everyone engaged in clinical research and patient care.

Since the publication of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Joint Position on the Disclosure of Clinical Trial Information, Napp has complied with the requirements to register and publish the outcomes of all trials that we have sponsored and that have been carried out in patients. Where possible, we publish data through peer-reviewed journals, but if this is not possible, we will share the data through a clinical trials registry, such as, or here on our website.

Further information on Napp sponsored studies

If you are searching for clinical studies involving our medicines, they may be available by searching for the medicine name on, or you can contact our Medical Information Team for advice.

Opioid Charter

For Mundipharma’s Charter on the responsible medical use of opioid analgesics in pain management click here.

Opioid Safety Statement

“Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is a requirement at initiation, maintenance and tapering down of opioid therapy.”